The Library

Browse by Warwick Author

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Official Date | Item Type | Funder | No Grouping
Jump to: 2020 | 2019 | 2018
Number of items: 8.

2020

Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B. et al.
(2020) Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40). pp. 1-190. doi:10.3310/hta24400

2019

Drayson, Mark T., Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T., Whittaker, Anna C., Hawkey, Peter, Low, Eric and Dunn, Janet A. (2019) Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62). pp. 1-94. doi:10.3310/hta23620

Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen B., Dawkins, Bryony et al.
(2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM) : a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. Oncology, 20 (12). pp. 1760-1772. doi:10.1016/S1470-2045(19)30506-6

Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel et al.
(2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191). pp. 2599-2612. doi:10.1016/S0140-6736(19)30650-6

2018

Chicca, I. J., Heaney, J. L. J., Iqbal, Gulnaz, Bowcock, S., Planche, T., Wood, J., Raynes, K., Hawkey, P., Pratt, G., Yong, K., Dunn, Janet A. and Drayson, M. T. (2018) Major changes in levels of regulatory cytokines and functional antibodies contribute to severe immunodeficiency of myeloma patients and persist at one year post diagnosis. Haematologica, 103 (Supplement 1). pp. 1-48. P02.

Bowcock, S., Atkin, C., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M. and Co-Investigators, Teamm (2018) Does a long diagnostic pathway in myeloma lead to more advanced disease at presentation? An analysis from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-PO-098 [pp 99]. doi:10.1111/bjh.15226

Bowcock, S., Planche, T., Iqbal, Gulnaz, Pratt, G., Yong, K., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M. and Co-Investigators, Teamm (2018) Levofloxacin prophylaxis in newly diagnosed myeloma reduces febrile episodes and death without increasing healthcare associated infections : results from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-OR-012 [pp16]. doi:10.1111/bjh.15226

Atkin, C., Drayson, M., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Higgins, Helen B., Dunn, Janet A. and Bowcock, S. (2018) Presenting symptoms of patients with multiple myeloma : data from the TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial. British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-PO-094 [pp 96]. doi:10.1111/bjh.15226

This list was generated on Fri May 20 11:32:09 2022 BST.